Pulmonary Pharmacology

Correct Answer

C — Fluticasone propionate

Rationale

Fluticasone propionate is classified as having very high glucocorticoid receptor binding affinity and very high lipophilicity among available inhaled corticosteroids. Its high lipophilicity dissolves it into airway epithelial cell membranes, creating intracellular drug depots that sustain prolonged glucocorticoid receptor occupancy and enable once- or twice-daily dosing. Budesonide has intermediate lipophilicity and achieves airway retention through a chemically distinct mechanism — reversible fatty acid conjugation rather than lipid solubility. Ciclesonide and beclomethasone dipropionate are prodrugs requiring activation by airway esterases, a separate classification category.

Correct Answer

A — Budesonide

Rationale

Budesonide forms reversible fatty acid conjugates within airway epithelial cells, a chemically distinct mechanism of local airway retention that prolongs glucocorticoid receptor occupancy without requiring high lipophilicity. Fluticasone propionate achieves prolonged retention through high lipophilicity, creating intracellular membrane depots — a different mechanism. Ciclesonide and beclomethasone dipropionate are classified as prodrugs that require activation by airway esterases; their retention mechanism is not fatty acid conjugation.

Correct Answer

D — Ciclesonide

Rationale

Ciclesonide is classified as a prodrug that is activated by airway esterases primarily in the lower airways, generating the active metabolite des-ciclesonide. This lower-airway selective activation reduces oropharyngeal drug deposition and its associated adverse effects. Beclomethasone dipropionate shares this prodrug classification. Fluticasone propionate and fluticasone furoate are active drugs, not prodrugs. Budesonide is also an active drug whose airway retention depends on intracellular fatty acid conjugation, not esterase activation.

Correct Answer

B — Dupilumab

Rationale

Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, the shared component of both the type I and type II interleukin-4/interleukin-13 receptor complexes. Omalizumab targets IgE. Mepolizumab targets interleukin-5 directly. Benralizumab targets the interleukin-5 receptor alpha subunit. Each biologic is defined by its specific molecular target, making these distinctions vocabulary-level classification knowledge.

Correct Answer

A — Omalizumab

Rationale

Omalizumab is classified as an anti-IgE monoclonal antibody. It binds free IgE at the same site recognized by the high-affinity IgE receptor on mast cells and basophils, preventing IgE from attaching to these cells and initiating allergic degranulation. Dupilumab targets the interleukin-4 receptor alpha subunit. Mepolizumab targets interleukin-5. Benralizumab targets the interleukin-5 receptor alpha subunit.

Correct Answer

C — Mepolizumab

Rationale

Mepolizumab is classified as a monoclonal antibody that binds and neutralizes interleukin-5 directly, preventing it from interacting with the interleukin-5 receptor on eosinophil precursors and mature eosinophils. Reslizumab shares this mechanism. Benralizumab differs by targeting the interleukin-5 receptor alpha subunit rather than the cytokine itself — an important distinction because receptor blockade also recruits natural killer cells to destroy eosinophils through antibody-dependent cellular cytotoxicity. Dupilumab targets interleukin-4 receptor alpha. Omalizumab targets IgE.

Correct Answer

D — Transrepression accounts for most anti-inflammatory benefit; transactivation accounts for most systemic adverse effects

Rationale

Glucocorticoid receptor transrepression — interaction with pro-inflammatory transcription factors including nuclear factor-kappa B and activator protein-1 — blocks cytokine gene transcription and accounts for most of the anti-inflammatory benefit of inhaled corticosteroids. Transactivation — direct binding of the glucocorticoid receptor to glucocorticoid response elements in the genome — induces gene expression, including some anti-inflammatory proteins, but also drives most systemic adverse effects such as glucose dysregulation, bone loss, and hypothalamic-pituitary-adrenal axis suppression. The ratio of transrepression to transactivation activity varies across ICS agents and is the basis for ongoing drug development aimed at dissociating benefit from harm.

Correct Answer

B — Rinsing removes deposited drug from oropharyngeal surfaces, reducing local glucocorticoid-mediated immune suppression

Rationale

Oral candidiasis develops because inhaled corticosteroid particles deposited in the oropharynx suppress local immune defenses, impairing clearance of Candida albicans. Rinsing with water and spitting physically removes deposited drug from oropharyngeal surfaces before it can suppress local immunity, substantially reducing incidence. This is a mechanical intervention targeting the drug deposition that drives the adverse effect. Rinsing and spitting also reduces systemic absorption from swallowed drug — a secondary benefit — but the primary mechanism of candidiasis prevention is removal of the local immunosuppressive stimulus, not alteration of gastric or salivary chemistry.

Correct Answer

C — Dysphonia results from glucocorticoid-induced myopathy of the intrinsic laryngeal muscles, not from surface drug deposition

Rationale

Dysphonia from inhaled corticosteroids is caused by glucocorticoid-induced myopathy of the intrinsic laryngeal muscles — the small muscles that control vocal cord tension and adduction. Because the mechanism is myopathic rather than related to surface drug deposition, removing deposited drug from the oropharynx does not prevent it. This mechanistic distinction separates dysphonia from oral candidiasis, which is prevented by rinsing precisely because candidiasis does arise from locally deposited drug suppressing oropharyngeal immunity. Management of dysphonia includes dose reduction, spacer use, or switching to ciclesonide, which has lower oropharyngeal deposition.

Correct Answer

A — Approximately 99% hepatic first-pass extraction inactivates the drug swallowed from the oropharynx before it reaches systemic circulation

Rationale

Fluticasone propionate has approximately 99% first-pass hepatic extraction, meaning that nearly all drug swallowed from the oropharynx is metabolized during its first pass through the liver before reaching the systemic circulation. This high extraction ratio is the principal pharmacokinetic basis for its favorable systemic safety profile despite oropharyngeal deposition. Budesonide has approximately 90% first-pass extraction by comparison. Fluticasone propionate is an active drug, not a prodrug requiring airway esterase activation — that classification applies to ciclesonide and beclomethasone dipropionate. Its lipophilicity promotes airway retention but does not prevent systemic absorption entirely.

Correct Answer

D — Asthma is driven by type 2 eosinophilic inflammation that is glucocorticoid-sensitive; COPD is driven by neutrophilic and macrophage-mediated inflammation that is largely glucocorticoid-resistant

Rationale

The differential ICS responsiveness between asthma and COPD is mechanistic, not empirical. Asthma is a type 2 immune-mediated disease driven by interleukin-4, interleukin-5, and interleukin-13 — cytokines whose transcription is potently suppressed by glucocorticoid receptor transrepression. Inhaled corticosteroids reduce eosinophilic inflammation, exacerbation frequency, and airway hyperresponsiveness substantially in asthma. COPD is driven by neutrophilic, macrophage-mediated, and CD8-positive T-cell inflammation triggered by cigarette smoke; these processes are far less sensitive to glucocorticoids, predicting the consistently smaller and more variable effect size of inhaled corticosteroids in COPD.

Correct Answer

B — Counts at or above 300 cells per microliter predict meaningful exacerbation reduction; counts below 100 predict little benefit and increased pneumonia risk

Rationale

Blood eosinophil count is the standard biomarker embedded in current GOLD guidelines for predicting ICS benefit in COPD. Counts at or above 300 cells per microliter are most consistently associated with meaningful reductions in exacerbation frequency, reflecting a type 2 eosinophilic component to inflammation that is glucocorticoid-sensitive. Counts below 100 cells per microliter predict little ICS benefit while conferring the class-wide risk of pneumonia — a clinically important harm-to-benefit imbalance that argues against ICS use in this subgroup. This threshold-guided approach reflects the heterogeneity of COPD inflammation rather than treating all patients as equivalent candidates for ICS therapy.

Correct Answer

C — Budesonide/formoterol; formoterol's rapid onset of 1 to 3 minutes enables it to serve as a rescue bronchodilator

Rationale

SMART uses budesonide/formoterol as both the scheduled daily controller and the as-needed reliever. The strategy is pharmacologically enabled by formoterol's combination of rapid onset — 1 to 3 minutes, comparable to albuterol — and long duration of approximately 12 hours. Salmeterol, with its slow onset of 10 to 20 minutes, cannot serve as a rescue bronchodilator and is therefore not suitable for SMART. An additional benefit of the SMART approach is that each rescue inhalation delivers a dose of budesonide alongside formoterol, providing anti-inflammatory coverage at the moment of symptomatic worsening when inflammation is most active.

Correct Answer

A — Systemically absorbed ICS suppresses hypothalamic CRH and pituitary ACTH secretion, reducing endogenous adrenal cortisol production

Rationale

A fraction of inhaled corticosteroid dose is absorbed systemically — either from the lung or from swallowed oropharyngeal drug. At high doses, this systemic absorption is sufficient for the absorbed glucocorticoid to suppress the hypothalamic-pituitary-adrenal axis through the normal negative feedback mechanism: suppression of hypothalamic corticotropin-releasing hormone and pituitary adrenocorticotropic hormone, which reduces adrenal cortisol production. At standard low-to-medium doses, this suppression is generally subclinical. At high doses — particularly above the equivalent of 1000 micrograms per day of fluticasone propionate — clinically meaningful suppression occurs, and patients are at risk for secondary adrenal insufficiency during surgical stress, severe illness, or abrupt ICS discontinuation.

Correct Answer

B — Adding a valved holding chamber (spacer) to the pressurized metered-dose inhaler, which reduces oropharyngeal deposition before drug reaches the oropharynx

Rationale

Oropharyngeal rinsing removes drug that has already deposited in the oropharynx, but a spacer (valved holding chamber) reduces the amount of drug that reaches the oropharynx in the first place. The spacer slows the aerosol plume and allows larger particles — which would otherwise impact the oropharynx — to settle in the chamber before inhalation, so that only finer respirable particles enter the airway. This dual mechanism reduces oropharyngeal deposition at the source while simultaneously improving lower airway delivery. In a patient who is already rinsing consistently and still developing recurrent candidiasis, adding a spacer addresses the residual deposition that rinsing cannot reverse. Prophylactic fluconazole treats the fungal consequence but does not reduce the immunosuppressive drug exposure driving it. Doubling rinse frequency provides no meaningful additional drug removal beyond a single thorough rinse-and-spit.

Correct Answer

D — His count falls between the high-benefit threshold of 300 and the low-benefit threshold of 100; ICS may provide some exacerbation reduction given his frequent exacerbation history, but with less certainty than at counts of 300 or above and with ongoing pneumonia risk to weigh

Rationale

Blood eosinophil count of 190 cells per microliter places this patient in the intermediate zone defined by GOLD guidelines — above the less-than-100 threshold that predicts little ICS benefit and increased pneumonia risk, but below the 300-or-above threshold that most consistently predicts meaningful exacerbation reduction. In this gray zone, the decision to add ICS requires integrating the biomarker with clinical context: three exacerbations per year despite optimized bronchodilator therapy is a substantial burden that may justify accepting the intermediate and uncertain ICS benefit alongside the class pneumonia risk. This is a judgment call rather than a clear threshold application, which is precisely what the two-threshold framework was designed to clarify — patients at the extremes get clear guidance, while patients in the middle require individualized reasoning balancing the expected magnitude of benefit against a real and class-wide adverse effect.

Correct Answer

A — Chronic high-dose ICS suppresses hypothalamic CRH and pituitary ACTH, reducing adrenal cortisol production and limiting the stress response capacity during surgery

Rationale

At high doses, the fraction of inhaled corticosteroid absorbed systemically is sufficient to suppress the hypothalamic-pituitary-adrenal axis through negative feedback: suppression of corticotropin-releasing hormone from the hypothalamus and adrenocorticotropic hormone from the pituitary reduces adrenal cortisol output. With chronic suppression, the adrenal glands may have insufficient reserve to mount the cortisol surge required to cope with the physiological stress of major surgery — a condition called secondary adrenal insufficiency. This is the mechanism underlying the clinical concern about stress-dose corticosteroids in patients on long-term high-dose ICS. The adrenal glands themselves remain structurally intact; the problem is insufficient stimulation from the suppressed pituitary-hypothalamic axis, not intrinsic adrenal damage.

Correct Answer

C — Dupilumab blocks the interleukin-4 receptor alpha subunit, simultaneously interrupting both interleukin-4 and interleukin-13 signaling; elevated fractional exhaled nitric oxide reflects active interleukin-13-driven inflammation that this dual blockade addresses

Rationale

Dupilumab targets the interleukin-4 receptor alpha subunit, which is the shared component of both the type I interleukin-4 receptor and the type II receptor through which interleukin-13 signals on airway structural cells. Blocking this shared subunit simultaneously prevents both interleukin-4 and interleukin-13 from signaling. Fractional exhaled nitric oxide is driven primarily by interleukin-13 and interleukin-4-mediated airway eosinophilic inflammation; an elevated value indicates active type 2 inflammatory pathway activity even when blood eosinophil counts are only mildly elevated. Unlike anti-interleukin-5 agents — which require blood eosinophil counts typically at or above 150 to 300 cells per microliter for eligibility — dupilumab is effective across a broader range of type 2 high disease, including patients whose dominant biomarker is elevated fractional exhaled nitric oxide rather than blood eosinophilia.